Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMAR QADIR MAJJHOO

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1255411039
CMS profile
284104
Location
SAINT CLAIR SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$421,816.64

677 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 14; records 201–250 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMAR QADIR MAJJHOO

NPI 1255411039 · CMS profile ID 284104

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SAINT CLAIR SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 14; records 201–250 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMAR QADIR MAJJHOO, NPI 1255411039, CMS profile ID 284104. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 14; records 201–250 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AMAR QADIR MAJJHOO, NPI 1255411039, CMS profile ID 284104. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 14; records 201–250 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AMAR QADIR MAJJHOO, NPI 1255411039, CMS profile ID 284104, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 14; records 201–250 of 677 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1255411039?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

677 matching records · $421,816.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 677 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 677.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $20.6109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673024615 CMS
Novartis Pharmaceuticals Corporation $2,525.0009/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659762883 CMS
Novartis Pharmaceuticals Corporation $121.9209/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659762886 CMS
AbbVie, Inc. $2,000.0009/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924969 CMS
AbbVie, Inc. $2,000.0009/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924971 CMS
Novartis Pharmaceuticals Corporation $22.2709/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659762895 CMS
Horizon Therapeutics plc $89.6709/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691436219 CMS
Horizon Therapeutics plc $21.4409/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691436225 CMS
Johnson & Johnson Health Care Systems Inc. $37.8909/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 644340945 CMS
Celgene Corporation $1,138.8009/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672954927 CMS
Celgene Corporation $247.2509/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672965791 CMS
Celgene Corporation $3,608.0009/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672972587 CMS
Celgene Corporation $121.6009/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672989873 CMS
GlaxoSmithKline, LLC. $20.0509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670643363 CMS
GlaxoSmithKline, LLC. $2.4909/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671142865 CMS
AbbVie, Inc. $18.6209/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924999 CMS
Novartis Pharmaceuticals Corporation $2,525.0009/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659762875 CMS
Novartis Pharmaceuticals Corporation $121.8409/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659762879 CMS
AbbVie, Inc. $2,000.0009/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924961 CMS
AbbVie, Inc. $2,000.0009/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924963 CMS
PFIZER INC. $13.0909/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673754795 CMS
Regeneron Healthcare Solutions, Inc. $35.2509/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673427671 CMS
Regeneron Healthcare Solutions, Inc. $443.1409/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673427675 CMS
AbbVie, Inc. $2,000.0009/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924957 CMS
AbbVie, Inc. $2,000.0009/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924959 CMS
Horizon Therapeutics plc $12.9609/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691436217 CMS
PFIZER INC. $2.6009/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673764295 CMS
Lilly USA, LLC $7.2109/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657666897 CMS
Genentech USA, Inc. $12.5609/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681401723 CMS
Horizon Therapeutics plc $128.7309/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691436213 CMS
Janssen Scientific Affairs, LLC $84.3609/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657600995 CMS
AbbVie, Inc. $7.6709/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647925063 CMS
E.R. Squibb & Sons, L.L.C. $15.1109/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651244735 CMS
E.R. Squibb & Sons, L.L.C. $0.2009/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651244737 CMS
Horizon Therapeutics plc $4.4208/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691436209 CMS
AbbVie, Inc. $400.0008/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647925061 CMS
Amgen Inc. $2,400.0008/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662167547 CMS
Amgen Inc. $400.0008/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662167549 CMS
Celgene Corporation $506.6108/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672953325 CMS
Celgene Corporation $4,718.0008/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672956297 CMS
Celgene Corporation $3,608.0008/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672956337 CMS
Celgene Corporation $23.7108/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672965991 CMS
Celgene Corporation $1,471.6008/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672966735 CMS
Celgene Corporation $183.2508/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672973993 CMS
Celgene Corporation $125.0008/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673032656 CMS
E.R. Squibb & Sons, L.L.C. $0.9208/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651244741 CMS
GlaxoSmithKline, LLC. $3,600.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671019529 CMS
Janssen Scientific Affairs, LLC $3,500.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657600993 CMS
AbbVie, Inc. $122.7008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647924965 CMS
Amgen Inc. $18.2608/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662167541 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $421,816.64 677
PY2020 $149,384.05 233
PY2021 $163,872.14 356
PY2022 $216,892.46 491
PY2023 $242,275.66 567
PY2024 $309,345.91 569
PY2025 $281,269.24 541

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,207,473.49 42
PY2024 Principal investigator $1,602,433.50 17
PY2023 Principal investigator $94,249.00 14
PY2022 Principal investigator $41,346.00 11
PY2021 Recipient $780.00 1
PY2021 Principal investigator $33,651.06 12
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $251,400.56 37
PY2019 Recipient $3,141.67 1
PY2019 Principal investigator $37,437.13 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $735.00 12/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175318416
Principal investigator 1 Janssen Research & Development, LLC $13,350.00 12/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318270
Principal investigator 1 Janssen Research & Development, LLC $145.00 12/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318341
Principal investigator 1 Janssen Research & Development, LLC $4,330.00 12/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318261
Principal investigator 1 Janssen Research & Development, LLC $360.00 12/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175318387
Principal investigator 1 Janssen Research & Development, LLC $735.00 11/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175318393
Principal investigator 1 Janssen Research & Development, LLC $14,700.00 11/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175318400
Principal investigator 1 Janssen Research & Development, LLC $5,939.00 11/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175318410
Principal investigator 1 Janssen Research & Development, LLC $448.00 11/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175318422
Principal investigator 1 Janssen Research & Development, LLC $2,165.00 11/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318191
Principal investigator 1 Janssen Research & Development, LLC $310.00 11/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318289
Principal investigator 1 Janssen Research & Development, LLC $1,825.00 11/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318253
Principal investigator 1 AstraZeneca UK Limited $5,598.00 10/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185537928
Principal investigator 1 Janssen Research & Development, LLC $35.00 09/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318230
Principal investigator 1 Janssen Research & Development, LLC $4,840.00 09/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318303
Principal investigator 1 Janssen Research & Development, LLC $180.00 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318347
Principal investigator 1 Janssen Research & Development, LLC $35.00 08/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318320
Principal investigator 1 Janssen Research & Development, LLC $2,120.00 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318215
Principal investigator 1 Amgen Inc. $2,782.16 07/28/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY PC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246648147
Principal investigator 1 Janssen Research & Development, LLC $35.00 07/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318335
Principal investigator 1 Janssen Research & Development, LLC $11,725.00 07/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318246
Principal investigator 1 Eli Lilly and Company $17,309.00 07/01/2025 Non-covered Recipient Entity
HENRY FORD MACOMB HEALTH CENTER
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187883396
Principal investigator 1 Janssen Research & Development, LLC $180.00 06/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318311
Principal investigator 1 Janssen Research & Development, LLC $4,330.00 06/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318356
Principal investigator 1 Janssen Research & Development, LLC $325.00 05/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318295
Principal investigator 1 Janssen Research & Development, LLC $345.00 05/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318328
Principal investigator 1 Janssen Research & Development, LLC $14,300.00 05/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318198
Principal investigator 1 Janssen Research & Development, LLC $35.00 05/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318372
Principal investigator 1 Janssen Research & Development, LLC $325.00 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318238
Principal investigator 1 Amgen Inc. $76,764.29 04/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246640319
Principal investigator 1 Amgen Inc. $59,960.67 04/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246640321
Principal investigator 1 Janssen Research & Development, LLC $35.00 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318225
Principal investigator 1 Janssen Research & Development, LLC $325.00 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318206
Principal investigator 1 Amgen Inc. $22,804.47 02/20/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246648151
Principal investigator 1 Amgen Inc. $60,251.78 02/19/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246648154
Principal investigator 1 Amgen Inc. $12,983.74 01/28/2025 Non-covered Recipient Entity
STAT RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246648708
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICH IGAN LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175318380
Principal investigator 1 Amgen Inc. $9,700.17 01/13/2025 Non-covered Recipient Entity
BRADENTON RESEARCH CENTER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639781
Principal investigator 1 AstraZeneca UK Limited $2,206.00 01/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN, LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185537930
Principal investigator 1 Janssen Research & Development, LLC $750.00 01/07/2025 Non-covered Recipient Entity
Clnc Rsrch Inst Of Michigan Llc
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175231797
Principal investigator 1 Amgen Inc. $11,604.05 01/03/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246648167
Principal investigator 1 Amgen Inc. $4,839,047.16 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246640323